Hepatic portal blockade and central venous pressure control were often used in hepatectomy to reduce bleeding and ensure a clear surgical field so that the operation can be carried out smoothly, but the process of hepatic portal blockade and opening can lead to hepatic ischemia-reperfusion injury (HIRI), gastrointestinal stagnation, and intestinal bacterial translocation. Therefore, perioperative measures to alleviate HIRI caused by hepatic portal blockade and to improve the safety of surgery have become a hot research topic in hepatic resection.Methods such as ischemic preconditioning, subcooling, drug therapy, and anti-apoptotic gene therapy have emerged, among which drug therapy has the characteristics of strong operability, relative safety, and easy access in clinic, and thus it has received extensive attention. This article summarizes the drugs and mechanisms that are representative of the improvements in HIRI, to provide reference for clinical diagnosis and treatment of HIRI.

1.谭思由, 陈文雁, 苏颖颖, 等. 肝脏缺血-再灌注损伤防治策略研究进展[J]. 临床麻醉学杂志, 2021, 37(10): 1106-1110. [Tan SY, Chen WY, Su YY, et al. Research progress on prevention and treatment strategies of hepatic ischemia-reperfusion injury[J]. Journal of Clinical Anaesthesiology, 2021, 37(10): 1106-1110.] DOI: 10.12089 /jca.2021.10.021.

2.邓银芝, 倪利华, 周中银, 等. 肝脏缺血再灌注损伤的机制及防治策略的研究进展[J]. 微循环学杂志, 2023, 33(2): 109-115. [Deng YZ, Ni LH, Zhou ZY, et al. Research progress on the mechanism and prevention strategies of hepatic ischemia-reperfusion injury[J]. Chinese Journal of Microcirculation, 2023, 33(2): 109-115.] DOI: 10.3969/j.issn.1005-1740.2023.02.020.

3.Xia H, Liu Z, Liang W, et al. Vagus nerve stimulation alleviates hepatic ischemia and reperfusion injury by regulating glutathione production and transformation[J]. Oxid Med Cell Longev, 2020, 2020: 1079129. DOI: 10.1155/2020/1079129.

4.蔡林林, 傅海龙, 张卿卿, 等. 还原型谷胱甘肽保护线粒体并减轻大鼠肝脏缺血再灌注损伤[J]. 第二军医大学学报, 2015, 36(12): 1300-1303. [Cai LL, Fu HL, Zhang QQ, et al. Glutathione protects mitochondrion and alleviates liver ischemia-reperfusion injury in rats[J]. Academic Journal of Naval Medical University, 2015, 36(12): 1300-1303.] DOI: 10.3724/SP.J1008.2015.01300.

5.Luo L, Mo G, Huang D. Ferroptosis in hepatic ischemia-reperfusion injury: regulatory mechanisms and new methods for therapy (Review)[J]. Mol Med Rep, 2021, 23(3): 225. DOI: 10.3892/mmr.2021.11864.

6.Gao Y, Li ZT, Jin L, et al. Melatonin attenuates hepatic ischemia-reperfusion injury in rats by inhibiting NF-κB signaling pathway[J]. Hepatobiliary Pancreat Dis Int, 2021, 20(6): 551-560. DOI: 10.1016/j.hbpd.2021.04.001.

7.Croome KP. N-acetylcysteine and reduction of ischemia-reperfusion injury in liver transplantation[J]. Transplantation, 2023, 107(9): 1874. DOI: 10.1097/TP.0000000000004598.

8.Jia D, Guo S, Jia Z, et al. N-Acetylcysteine in the donor, recipient, or both donor and recipient in liver transplantation: a systematic review with meta-analysis and trial sequential analysis[J]. Transplantation, 2023, 107(9): 1976-1990. DOI: 10.1097/TP.0000000000004597.

9.Liggett JR, Kang J, Ranjit S, et al. Oral N-acetylcysteine decreases IFN-γ production and ameliorates ischemia-reperfusion injury in steatotic livers[J]. Front Immunol, 2022, 13: 898799. DOI: 10.3389/fimmu.2022.898799.

10.Guan Y, Yao W, Yi K, et al. Nanotheranostics for the management of hepatic ischemia-reperfusion injury[J]. Small, 2021, 17(23): e2007727. DOI: 10.1002/smll.202007727.

11.Kim JY, Lee DY, Kang S, et al. Bilirubin nanoparticle preconditioning protects against hepatic ischemia-reperfusion injury[J]. Biomaterials, 2017, 133: 1-10. DOI: 10.1016/j.biomaterials.2017.04.011.

12.Choi EK, Lim DG. Hepatic ischemia-reperfusion injury with respect to oxidative stress and inflammatory response: a narrative review[J]. J Yeungnam Med Sci, 2023, 40(2): 115-122. DOI: 10.12701/jyms.2022.00017.

13.Liu L, Zhang C, Lu T, et al. The efficacy and safety of glucocorticoid for perioperative patients with hepatectomy: a systematic review and meta-analysis[J]. Expert Rev Gastroenterol Hepatol, 2023, 17(1): 59-71. DOI: 10.1080/17474124.2023.2162878.

14.Donadon M, Molinari AF, Corazzi F, et al. Pharmacological modulation of ischemic-reperfusion injury during Pringle maneuver in hepatic surgery. A prospective randomized pilot study[J]. World J Surg, 2016, 40(9): 2202-2212. DOI: 10.1007/s00268-016-3506-1.

15.Hasegawa Y, Nitta H, Takahara T, et al. Glucocorticoid use and ischemia-reperfusion injury in laparoscopic liver resection: randomized controlled trial[J]. Ann Gastroent Surg, 2019, 4(1): 76-83. DOI: 10.1002/ags3.12298.

16.Bressan AK, Isherwood S, Bathe OF, et al. Preoperative single-dose methylprednisolone prevents surgical site infections after major liver resection: a randomized controlled trial[J]. Ann Surg, 2022, 275(2): 281-287. DOI: 10.1097/SLA.0000000000004720.

17.伍俊妍, 余晓霞, 林茵. 围手术期糖皮质激素医-药专家共识[J]. 今日药学, 2021, 31(10): 721-732. [Wu JY, Yu XX, Lin Y. Expert consensus on the perioperative glucocorticoids management[J]. Pharmacy Today, 2021, 31(10): 721-732.] DOI: 10.12048/j.issn.1674-229X.2021.10.001.

18.中华医学会内分泌学分会, 中国内分泌代谢病专科联盟. 糖皮质激素类药物临床应用指导原则（2023版）[J]. 中华内分泌代谢杂志, 2023, 39(4): 289-296. [Chinese Society of Endocrinology, China Endocrinology and Metabolism Specialist Alliance. Principles for clinical application of glucocorticoids (2023 edition)[J]. Chinese Journal of Endocrinology and Metabolism, 2023, 39(4): 289-296.] DOI: 10.3760./cma.j.cn311282-20230116-00029.

19.廖永晖, 钟鼎文, 何勇, 等. 地塞米松联合肝切除术对原发性肝癌患者术后血清炎症介质及肝功能的影响[J]. 中国药物经济学, 2019, 14(12): 86-88. [Liao YH, Zhong DW, He Y, et al. Effects of dexamethasone combined with hepatectomy on serum inflammatory mediators and liver function in patients with primary liver cancer[J]. China Journal of Pharmaceutical Economics, 2019, 14(12): 86-88.] DOI: 10.12010/j.issn.1673-5846.2019.12.022.

20.何承峻, 杨小丁, 刘李, 等. 围手术期糖皮质激素对肝癌肝切除患者术后肝功能恢复的影响[J]. 肝胆胰外科杂志, 2020, 32(9): 553-556. [He CJ, Yang XD, Liu L, et al. Effects of perioperative glucocorticoids on postoperative liver function recovery in patients with hepatocellular carcinoma undergoing hepatic resection[J]. Journal of Hepatopancreatobiliary Surgery, 2020, 32(9): 553-556.] DOI: 10.11952/j.issn.1007-1954.2020.09.009.

21.夏魏. 小剂量糖皮质激素联合肝部分切除术对肝内胆管结石患者术后残余及肝功能的影响[J]. 微量元素与健康研究, 2020, 37(3): 30-31, 35. [Xia W. Effects of low-dose glucocorticoids combined with partial hepatectomy on postoperative residual and liver function in patients with intrahepatic bile duct stones[J]. Studies of Trace Elements and Health, 2020, 37(3): 30-31, 35.] https://www.nstl.gov.cn/paper_detail.html?id=7e797f650c07f3489314f1685e1d89c5.

22.彭浪, 吴兆平, 刘合春, 等. 原发性肝癌术后应用糖皮质激素对肝脏功能保护的临床研究[J]. 现代医药卫生, 2021, 37(2): 281-284. [Peng L, Wu ZP, Liu HC, et al. Clinical study on the protection of liver function by applying glucocorticoids after primary liver cancer surgery[J]. Journal of Modern Medicine & Health, 2021, 37(2): 281-284.] DOI: 10.3969/j.issn.1009-5519.2021.02.029.

23.陈亚茹, 胡宇凡, 闫瑾, 等. 药物预处理在肝脏缺血再灌注损伤中的保护作用研究进展[J]. 空军军医大学学报, 2024, 45(1): 43-47. [Chen YR, Hu YF, Yan J, et al. Research progress on the protective effect of pharmacological preconditioning on hepatic ischemic-reperfusion injury[J]. Journal of Air Force Medical University, 2024, 45(1): 43-47.] DOI: 10.13276/j.issn.2097-1656.2024.01.010.

24.Fouda AM, Youssef AR, Sharaf Eldin O. Comparative study of amlodipine vs. cilnidipine for the prevention of hepatic ischemia-reperfusion injury in rat model[J]. Fundam Clin Pharmacol, 2018, 32(2): 163-173. DOI: 10.1111/fcp.12335.

25.汪泽. 维拉帕米联合卡托普利对家兔心肌缺血再灌注损伤的保护作用[J]. 中国药物经济学, 2018, 13(9): 68-70. [Wang Z. Protective effect of Vera Pammy combined with Kato Pury on myocardial ischemia reperfusion injury in rabbits[J]. China Journal of Pharmaceutical Economics, 2018, 13(9): 68-70.] DOI: 10.12010/j.issn.1673-5846.2018.09.017.

26.Jones SM, Thurman RG. L-arginine minimizes reperfusion injury in a low-flow, reflow model of liver perfusion[J]. Hepatology, 1996, 24(1): 163-168. DOI: 10.1002/hep.510240127.

27.卢嘉宾, 兰祖, 韦庆, 等. 波生坦联合西地那非在先天性心脏病合并肺动脉高压患者中的应用进展[J]. 中国当代医药, 2023, 30(3): 53-56. [Lu GB, Lan Z, Wei Q, et al. Progress of Bosentan combined with Sildenafil in patients with congenital heart disease complicated with pulmonary hypertension[J]. China Modern Medicine, 2023, 30(3): 53-56.] DOI: 10.3969/j.issn.1674-4721. 2023.03.014.

28.Ge M, Chen H, Zhu Q, et al. Propofol post-conditioning alleviates hepatic ischaemia reperfusion injury via BRG1-mediated Nrf2/HO-1 transcriptional activation in human and mice[J]. J Cell Mol Med, 2017, 21(12): 3693-3704. DOI: 10.1111/jcmm.13279.

29.Wu Y, Qiu G, Zhang H, et al. Dexmedetomidine alleviates hepatic ischaemia-reperfusion injury via the PI3K/AKT/Nrf2-NLRP3 pathway[J]. J Cell Mol Med, 2021, 25(21): 9983-9994. DOI: 10.1111/jcmm.16871.

30.Wei L, Chen WY, Hu T, et al. Effect and mechanism of propofol in hepatic ischemia/reperfusion injury of rat[J]. Eur Rev Med Pharmaco Sci, 2021, 25(12): 4185. DOI: 10.26355/eurrev_202106_26115.

31.张丽媛, 李芙蓉, 王超, 等. p53对铁死亡的调节作用及潜在应用[J]. 中国病理生理杂志, 2019, 35(12): 2299-2304. [Zhang LY, Li FR, Wang C, et al. Emerging roles of p53 in ferroptosis and its potential application[J]. Chinese Journal of Pathophysiology, 2019, 35(12): 2299-2304.] DOI: 10.3969/j.issn.1000-4718.2019.12.029.

32.胡淼, 门运政, 陈蕾, 等. 右美托咪定通过抑制铁死亡发挥对小鼠脑缺血再灌注损伤的保护作用[J]. 中南大学学报(医学版), 2022, 47(5): 600-609. [Hu M, Men YZ, Chen L, et al. Dexmedetomidine exerts its protective effect on cerebral ischemia reperfusion injury in mice by inhibiting ferroptosis[J]. Journal of Central South University (Medical Science), 2022, 47(5): 600-609.] DOI: 10.11817/j.issn.1672-7347.2022.210443.